Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study

Trial Profile

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Nov 2018

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms XIENCE V USA-Phase 1; XIENCE-V-USA; XVU-Phase 1
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 25 Sep 2018 Results of a pooled analysis from XIENCEV USA, XIENCEV Japan, XIENCE V China and XIENCE V India trials presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
    • 25 Sep 2018 Results of a pooled analysis from post-approval registries XIENCE V USA, XIENCE V Japan, and XIENCE V India (n=8020) presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
    • 25 Sep 2018 Results of a pooled analysis assessing long-term clinical outcomes and predictors of MI in high bleeding risk-ACS pts in XIENCE V USA, XIENCE V Japan, XIENCE V China and XIENCE V India studies, presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top